CAS: 524-63-0; 4-((R)-Hydroxy((1S,2S,4S,5R)-5-Vinylquinuclidin-2-yl)Methyl)Quinolin-6-Ol

相似化合物

130-95-0 56-54-2 130-89-2

上下游产品

奎宁 Quinine 130-95-0
Quinine 130-95-0

奎宁置于三溴化硼体系中,用 二氯甲烷 作为反应溶剂,以99%的收率获得产物铜色树碱
参考文献:蒽酮的不对称烷基化,(-)-和 (+)-绿藻毒素 B 及其类似物的对映选择性全合成:绝对构型和有效抗菌剂
标题:蒽酮的不对称烷基化,(-)-和 (+)-绿藻毒素 B 及其类似物的对映选择性全合成:绝对构型和有效抗菌剂
摘要:描述了使用奎尼丁或奎宁衍生的催化剂相转移催化蒽酮与环状烯丙基溴的不对称烷基化.利用温和的碱性条件和低至 0.5 Mol % 的催化剂负载量,并实现高达 > 99:1 Dr 的选择性,这种不对称反应成功地应用于对映选择性地产生 (-)-和 (+)-绿藻毒素 B,从而允许分配这种天然抗生素的绝对构型.虽然开发的 C10 取代蒽酮的不对称合成有望在有机合成中找到更广泛的应用,但其直接应用于构建各种设计的 Viridicatumtoxin B 的对映体纯类似物,导致发现了高效但更简单的分子类似物.
DOI:10.1021/jacs.6B12654

专利信息

专利号:US-5900227-A
优先权日:1996-06-17
标题 :Multicyclic nitrone spin trapping compositions
发明人：JANZEN EDWARD G; SANKURATRI NAGARAJU
权利人:OKLAHOMA MED RES FOUND
摘要:Multicyclic nitrone spin trapping compounds capable of forming stable free radical spin adducts are provided as well as methods for their synthesis. The multicyclic nitrone spin trapping compounds can be reacted with a free radical, such as a hydroxy or hydroperoxy radical, in solution to form a spin adduct which is stable and readily detectable by electron paramagnetic resonance (EPR) spectroscopy. The multicyclic nitrone spin traps can be used to detect free radicals in a sample such as a biological system. In one embodiment, the spin trapping compound, 1,3,3-trimethyl-6-azabicyclo-[3.2.1]oct-6-ene-N-oxide ('TRAZON') is provided, as well as methods for the synthesis of TRAZON and of modified forms of TRAZON. TRAZON can react with a wide range of different free radicals in solution to form free radical spin adducts which are readily detectable by EPR.

专利号:US-11034695-B2
优先权日:2016-09-23
标 题:Dopamine-β-hydroxylase inhibitors
发明人：SOARES DA SILVA PATRÃ?CIO; ROSSI TINO; KISS LASZLO ERNO; BELIAEV ALEXANDER; LEAL PALMA PEDRO NUNO
权利人:BIAL—PORTELA & CA S A; BIAL—PORTELA & Cᵃ S A
摘要:This invention relates to: (a) compounds of Formula Ia (with R1, R4, R5, R6, n and A as defined herein) and pharmaceutically acceptable salts or solvates thereof that are useful as dopamine-β-hydroxylase inhibitors; (b) pharmaceutical compositions comprising such compounds, salts or solvates; (c) the use of such compounds, salts or solvates in therapy; (d) therapeutic methods of treatment using such compounds, salts or solvates; and (e) processes and intermediates useful for the synthesis of such compounds.